BioNTech Co-Founders to Depart Amid New Venture Launch; BNTX Shares Drop 8.3%

The leadership transition at BioNTech, the German biotech firm behind the first FDA-approved mRNA COVID-19 vaccine, has sent ripples through the healthcare sector. Co-founders Prof. Ugur Sahin and Dr. Özlem Türeci, who have served as co-CEOs since the company's inception in 2008, announced plans to leave the company to establish a new entity centered on advancing mRNA-based treatments for cancer and rare genetic diseases. The move follows a decade of transformative innovation, including the rapid development and deployment of the BNT162b2 vaccine. The departure comes at a pivotal moment as BioNTech continues to expand its pipeline beyond infectious diseases into oncology and autoimmune conditions. The company reported $2.3 billion in revenue for 2025, with over 60% derived from its collaboration with Pfizer. However, the transition of its founding leadership—key figures during the pandemic-era surge—has raised questions about the stability of its innovation roadmap and long-term execution capability. On March 10, 2026, BioNTech’s stock (BNTX) closed at $143.20, down 8.3% from the previous day’s close. The broader healthcare sector, tracked by the SPDR Health Care ETF (XLV), saw a modest 0.5% decline, while the IEX index (IEX) registered a 0.2% dip, suggesting the sell-off was company-specific rather than market-wide. Analysts note that while the new venture may enhance scientific leadership, the absence of Sahin and Türeci could create short-term volatility and delay key clinical milestones. The board has initiated a search for new leadership, with interim executives expected to assume roles immediately. Investors are now closely monitoring the company’s upcoming Q1 earnings call and the timeline for appointing a permanent CEO. The transition underscores the challenges faced by high-growth biotechs in retaining visionary leadership beyond early breakthroughs.